Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer

Breast Cancer Clinical Trial

— OVINTRA  

Official title:

A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01242449
• Other study ID #: 2010-021618-42
• Status: Completed
• Phase: Phase 2
• First received: November 16, 2010
• Last updated: May 20, 2015
• Start date: November 2010
• Est. completion date: October 2014

Study information

• Verified date: March 2015
• Source: Vejle Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer.

Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: October 2014
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Woman = 18 years of age.

• PS 0-2. Expected lifetime of more than 12 weeks.

• Histologically verified breast cancer(adenocarcinoma)

• Primary tumor or metastasis is HER2 positive with IHC3+ or FISH+ (ratio = 2.2).

• Documented metastatic breast cancer with min. one lesion measureable according to the RECIST 1.1 criteria. All solitary lesions must be verified cytologically/histologically if representing the only evidence of malignancy.

• The patient may have received (neo-) adjuvant chemotherapy (taxanes, anthracyclines and trastuzumab) and 1st line chemotherapy in combination with trastuzumab for metastatic disease.

• The patient may have received previous adjuvant antihormonal treatment for metastatic breast cancer.

• The patient may receive radiation therapy, however, not against lesions used for response evaluation.

• Normal heart function, LVEF = 50% measured by MUGA/EKKO.

• Normal bone marrow function: Hemoglobin = 6 mmol/l, ANC = 1.5x10^9/l. Thrombocytes = 100x10^9/l.

• Normal liver function: Bilirubin = 1.5 x upper normal level, ALAT = 2.5 x upper normal level, BASP = 2.5 x upper normal level (= 5 if presence of bone metastases).

• Normal renal function: Creatinine = upper normal level. In case of raised creatinine the measured/calculated GFR must be = 50 ml/min.

• Fertile women must present a negative pregnancy test and use contraceptives during and 3 months after treatment. An IUD without hormone is considered a safe contraceptive.

• Written and orally informed consent prior to any study related procedure.

Exclusion Criteria:

• Local recurrence or counter-lateral breast cancer without other dissemination.

• Pregnant or breastfeeding women.

• Clinical symptoms of CNS metastases, incl. meningeal carcinomatosis.

• Malabsorption syndrome or other disease affecting the gastrointestinal function. Resection of the ventriculus or the small intestine, which can affect absorption of oral vinorelbine.

• Dysphagia or other conditions preventing the patient from swallowing tablets.

• Mental or social conditions preventing treatment or follow-up.

• Serious concurrent medical condition, such as:

• AMI within 12 months or unstable angina.

• Heart incompensation NYHA III or IV or uncontrolled hypertension (systolic > 150 mm/hg and/or diastolic >100 mm/hg).

• Serious arrythmia requiring medication, excl. atrial fibrillation and paroxystic supraventricular tachycardia.

• Active infection, uncontrolled diabetes or hypercalcemia.

• Other concurrent experimental treatment.

• Concurrent antihormonal treatment of metastatic breast cancer.

• Known neuropathia = grade 2.

• Other previous malignant disease within the past 5 years excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri.

• Previous treatment with vinca alkaloid.

• Previous serious allergic or unexpected reactions to trastuzumab treatment.

Study Design

Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Trastuzumab
Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
• Vinorelbine
Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.

Locations

Country	Name	City	State
Denmark	Dept. of Oncology, Aalborg Sygehus	Aalborg
Denmark	Dept. of Oncology, Esbjerg Hospital	Esbjerg
Denmark	Department of Oncology, Vejle Hospital	Vejle

Sponsors (1)

Lead Sponsor	Collaborator
Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate	CT scan and MUGA scan	Every 9 weeks. Up to 2 years	No
Secondary	Progression free survival	CT scan	Every 9 weeks from date of first treatment until progression or death. Up to 2 years	No
Secondary	Overall Survival		From date of inclusion until date of death. Up to 2 years.	No